Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

60; Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.ISIS PHARMACEUTICALS, INC.SELECTED FINANCIAL INFORMATIONCondensed Consolidated Statements of Operations(In Thousands, Except Per Share Data)Three months ended,March 31,20122011Revenue:(unaudited)Research and development revenueunder collaborative agreements$21,818
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
3. Halozyme Reports First Quarter 2012 Financial Results
4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. IRIDEX Reports 2012 First Quarter Results
7. Cambrex Reports First Quarter 2012 Results
8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
11. Neuland Labs Reports Financial Results For Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:8/28/2015)... ... 2015 , ... Approximately 2,000 United Methodists are expected to ... children, a thank you to the many creative and generous ways in which ... Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium event, ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, ... as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held ... was to raise money to support music education programs in the underfunded local school ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... 16, 2009 A new study published in ... almost twice as high in people with epilepsy compared ... minorities have seven times the odds of depression in ... show that 40 percent of depressed respondents with epilepsy ...
... test capable of confirming or ruling out Alzheimer,s disease ... University of Pennsylvania School of Medicine. By measuring cerebrospinal ... hallmarks amyloid beta42 peptide and tau protein ... impairment would convert to Alzheimer,s disease over time. Researchers ...
... proudly announces that the Peyton Manning Children,s Hospital at ... 6th Annual Talk Walk Run 2009 fundraiser benefiting deaf ... more than 30 years, Hear Indiana has helped children ... members of society," said R. Christopher Miyamoto, pediatric ENT ...
... Will Deliver Educational Training and Professional Certification ... PulseLearning, a leading Ireland-based provider of ... to develop customized eLearning and certification programs ... Casualty Underwriters and the Insurance Institute of ...
... 16 OrbusNeich Medical, Inc. ("Orbus" or the "Company"), ... devices for the treatment of vascular diseases, today announced ... Corporation ("BSC"). The lawsuit, filed in the United ... asserts claims against BSC for patent infringement, breach of ...
... a novel genetic technology that covers up genetic errors, ... Health have developed a successful treatment for dogs with ... and ultimately fatal, muscle disease. , The technology, known ... as molecular "patches." These patches cover up mutant DNA ...
Cached Medicine News:Health News:Depression twice as likely in seizure sufferers 2Health News:Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease 2Health News:Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease 3Health News:Peyton Manning Children's Hospital at St. Vincent Will Serve As Lead Sponsor of Hear Indiana's 6th Annual Talk Walk Run 2009 2Health News:Ireland's PulseLearning Inks Agreement With Leading U.S. Insurance Industry Association 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 3Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 2Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 3
The IgA in vitro diagnostic enzyme immunoassay is intended for the qualitative detection of anti-human tTG IgA antibodies in human serum as an aid in the diagnosis of CD....
...
... The FIDIS system and its ... simultaneously and on the same sample, ... dedicated to all types of laboratories ... than today their daily routine, as ...
The PICO50 is used for arterial line sampling....
Medicine Products: